The S&P 500, Nasdaq and Dow all fell for the week, while pharmaceutical stocks slid after Trump picked anti-vaccine activist ...

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr.

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...

Fintel reports that on November 14, 2024, Citigroup initiated coverage of Amgen (NasdaqGS:AMGN) with a Neutral recommendation ...

2 Dividend Stocks to Buy Hand Over Fist in November was originally published by The Motley Fool Their recent issues are ...

Key Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...

In a report released today, Umer Raffat from Evercore ISI maintained a Buy rating on Amgen (AMGN – Research Report). The company’s ...

Only 12 of the index’s stocks were on the rise, and among the laggards were firms that boast larger stock prices like Salesforce, International Business Machines, Amgen, and UnitedHealth Group. The ...

On Wednesday, Amgen Inc (AMGN) stock saw a modest uptick, ending the day at $301.44 which represents a slight increase of $2.60 or 0.87% from the prior close of $298.84. The stock opened at $306 and ...

Analysts have set 12-month price targets for Amgen, revealing an average target of $349.0, a high estimate of $405.00, and a ...

Researchers are exploring how small airway abnormalities in younger smokers could help identify who is at risk of developing COPD and establish how the chronic lung disease progresses.

Shares of pharmaceutical giant Amgen (AMGN) are attempting to bounce back after suffering a steep drop of 7.1% yesterday.